<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35553332</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-4978</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular biology reports</Title>
          <ISOAbbreviation>Mol Biol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The role of potassium channels in the proliferation and migration of endometrial adenocarcinoma HEC1-A cells.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-022-07546-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endometrial cancer is the most common gynecological cancer in developed countries. Potassium channels, which have many types, are suggested to play a major role in cancer progression. However, their role in endometrial cancer has not been fully investigated. We aimed to demonstrate whether the ATP-sensitive potassium channel blocker glibenclamide, voltage-sensitive potassium channel blocker 4-aminopyridine, non-selective (voltage-sensitive and calcium-activated) potassium channels blocker tetraethylammonium and potassium chloride (KCl) have any effect on the proliferation and migration of HEC1-A cells.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Proliferation and migration were evaluated by real-time cell analysis (xCELLigence system) and wound healing assays, respectively. Proliferation was reduced by glibenclamide (0.1 and 0.2 mM, P &lt; 0.05 and P &lt; 0.01, respectively), 4-aminopyridine (10 and 20 mM, P &lt; 0.001) and tetraethylammonium (10 and 20 mM, P &lt; 0.01 and P &lt; 0.001, respectively). However, KCl did not change the proliferation. Migration was reduced by glibenclamide (0.01, 0.1 and 0.2 mM, P &lt; 0.001, P &lt; 0.001 and P &lt; 0.01, respectively) and 4-aminopyridine (10 and 20 mM, P &lt; 0.05 and P &lt; 0.01, respectively). Tetraethylammonium did not change migration. However, KCl reduced it (10, 25 and 50 mM, P &lt; 0.05, P &lt; 0.01 and P &lt; 0.01, respectively). Both proliferation and migration were reduced by glibenclamide and 4-aminopyridine. However, tetraethylammonium only reduced proliferation and KCl only reduced migration.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Potassium channels have an important role in HEC1-A cell proliferation and migration and potassium channel blockers needs to be further investigated for their therapeutic effect in endometrial cancer.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Erdem Kış</LastName>
            <ForeName>Emel</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-0056-5143</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Pharmacology, Faculty of Medicine, University of Mersin, Campus Çiftlikköy, 33343, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tiftik</LastName>
            <ForeName>R Nalan</ForeName>
            <Initials>RN</Initials>
            <Identifier Source="ORCID">0000-0001-7277-3369</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Pharmacology, Faculty of Medicine, University of Mersin, Campus Çiftlikköy, 33343, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al Hennawi</LastName>
            <ForeName>Khairat</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-5821-9556</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Pharmacology, Faculty of Medicine, University of Mersin, Campus Çiftlikköy, 33343, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ün</LastName>
            <ForeName>İsmail</ForeName>
            <Initials>İ</Initials>
            <Identifier Source="ORCID">0000-0001-6442-4185</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Pharmacology, Faculty of Medicine, University of Mersin, Campus Çiftlikköy, 33343, Mersin, Turkey. unisfarma@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Mol Biol Rep</MedlineTA>
        <NlmUniqueID>0403234</NlmUniqueID>
        <ISSNLinking>0301-4851</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">4-Aminopyridine</Keyword>
        <Keyword MajorTopicYN="N">Endometrium adenocarcinoma</Keyword>
        <Keyword MajorTopicYN="N">Glibenclamide</Keyword>
        <Keyword MajorTopicYN="N">KCl</Keyword>
        <Keyword MajorTopicYN="N">Tetraethylammonium</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>14</Hour>
          <Minute>59</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35553332</ArticleId>
        <ArticleId IdType="doi">10.1007/s11033-022-07546-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s11033-022-07546-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104. https://doi.org/10.1016/j.ijgo.2009.02.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijgo.2009.02.012</ArticleId>
            <ArticleId IdType="pubmed">19367689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21492</ArticleId>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, Linkov F (2010) Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 21(11):1851–1856. https://doi.org/10.1007/s10552-010-9612-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10552-010-9612-8</ArticleId>
            <ArticleId IdType="pubmed">20628804</ArticleId>
            <ArticleId IdType="pmc">2962676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S (2011) Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer 104(9):1505–1510</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2011.68</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander SPH, Mathie A, Peters JA, Veale EL, Striessnig J, Kelly E, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA, Collaborators CGTP (2019) The concise guide to pharmacology 2019/20: ion channel. Br J Pharmacol 176(S1):142–228. https://doi.org/10.1111/bph.14749</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.14749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day ML, Pickering SJ, Johnson MH, Cook DI (1993) Cell-cycle control of a large-conductance K<sup>+</sup> channel in mouse early embryos. Nature 65(6446):560–562. https://doi.org/10.1038/365560a0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/365560a0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wonderlin WF, Woodfork KA, Strobl JS (1995) Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle. J Cell Physiol 165(1):177–185. https://doi.org/10.1002/jcp.1041650121</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.1041650121</ArticleId>
            <ArticleId IdType="pubmed">7559799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Chiang C, Cooper MK, Northcott PA, Taylor MD, Barnes MJ, Tihan T, Chen J, Hackett CS, Weiss WA, James CD, Rowitch DH, Shuman MA, Jan YN, Jan LY (2012) Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev 26(16):1780–1796. https://doi.org/10.1101/gad.193789.112</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.193789.112</ArticleId>
            <ArticleId IdType="pubmed">22855790</ArticleId>
            <ArticleId IdType="pmc">3426758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bi D, Toyama K, Lemaître V, Takai J, Fan F, Jenkins D, Wulff H, Gutterman D, Park F, Miura H (2013) The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem 288(22):15843–15853. https://doi.org/10.1074/jbc.M112.427187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.427187</ArticleId>
            <ArticleId IdType="pubmed">23609438</ArticleId>
            <ArticleId IdType="pmc">3668741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monteith GR, Davis FM, Roberts-Thomson SJ (2012) Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 287(38):31666–31673. https://doi.org/10.1074/jbc.R112.343061</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.R112.343061</ArticleId>
            <ArticleId IdType="pubmed">22822055</ArticleId>
            <ArticleId IdType="pmc">3442501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun XX, Bostrom SL, Griffith LC (2009) Alternative splicing of the eag potassium channel gene in Drosophila generates a novel signal transduction scaffolding protein. Mol Cell Neurosci 40(3):338–343. https://doi.org/10.1016/j.mcn.2008.11.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mcn.2008.11.005</ArticleId>
            <ArticleId IdType="pubmed">19130887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Innamaa A, Jackson L, Asher V, Van Shalkwyk G, Warren A, Hay D, Bali A, Sowter A, Khan R (2013) Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer Res 33(4):1401–1408</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23564779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Innamaa A, Jackson L, Asher V, Van Schalkwyk G, Warren A, Hay D, Bali A, Sowter A, Khan R (2013) Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer. Clin Transl Oncol 15(11):910–918. https://doi.org/10.1007/s12094-013-1022-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-013-1022-4</ArticleId>
            <ArticleId IdType="pubmed">23479219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ousingsawat J, Spitzner M, Puntheeranurak S, Terracciano L, Tornillo L, Bubendorf L, Kunzelmann K, Schreiber R (2007) Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res 13(3):824–831. https://doi.org/10.1158/1078-0432.CCR-06-1940</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-1940</ArticleId>
            <ArticleId IdType="pubmed">17289873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menéndez ST, Villaronga MÁ, Rodrigo JP, Álvarez-Teijeiro S, García-Carracedo D, Urdinguio RG, Fraga MF, Pardo LA, Viloria CG, Suárez C, García-Pedrero JM (2012) Frequent aberrant expression of the human ether à go–go (hEAG1) potassium channel in head and neck cancer: pathobiological mechanisms and clinical implications. J Mol Med (Berl) 90(10):1173–1184. https://doi.org/10.1007/s00109-012-0893-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00109-012-0893-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venturini E, Leanza L, Azzolini M, Kadow S, Mattarei A, Weller M, Tabatabai G, Edwards MJ, Zoratti M, Paradisi C, Szabò I, Gulbins E, Becker KA (2017) Targeting the potassium channel Kv1.3 kills glioblastoma cells. Neurosignals 25(1):26–38. https://doi.org/10.1159/000480643</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000480643</ArticleId>
            <ArticleId IdType="pubmed">28869943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ru Q, Li WL, Xiong Q, Chen L, Tian X, Li CY (2018) Voltage-gated potassium channel blocker 4-aminopyridine induces glioma cell apoptosis by reducing expression of microRNA-10b-5p. Mol Biol Cell 29(9):1125–1136. https://doi.org/10.1091/mbc.E17-02-0120</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.E17-02-0120</ArticleId>
            <ArticleId IdType="pubmed">29514931</ArticleId>
            <ArticleId IdType="pmc">5921578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ru Q, Tian X, Wu YX, Wu RH, Pi MS, Li CY (2013) Voltage-gated and ATP-sensitive K<sup>+</sup> channels are associated with cell proliferation and tumorigenesis of human glioma. Oncol Rep 31(2):842–848. https://doi.org/10.3892/or.2013.2875</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2013.2875</ArticleId>
            <ArticleId IdType="pubmed">24284968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freise C, Ruehl M, Seehofer D, Hoyer J, Somasundaram R (2013) The inhibitor of Ca<sup>2+</sup>-dependent K<sup>+</sup> channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB. Invest New Drugs 31(2):452–457. https://doi.org/10.1007/s10637-012-9879-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10637-012-9879-6</ArticleId>
            <ArticleId IdType="pubmed">23054207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jäger H, Dreker T, Buck A, Giehl K, Gress T, Grissmer S (2004) Blockage of intermediate-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 65(3):630–638. https://doi.org/10.1124/mol.65.3.630</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.65.3.630</ArticleId>
            <ArticleId IdType="pubmed">14978241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schickling BM, England SK, Aykin-Burns N, Norian LA, Leslie KK, Frieden-Korovkina VP (2014) BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathway. Oncol Rep 33(2):533–538. https://doi.org/10.3892/or.2014.3617</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2014.3617</ArticleId>
            <ArticleId IdType="pubmed">25422049</ArticleId>
            <ArticleId IdType="pmc">4306270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdul M, Hoosein N (2002) Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett 186(1):99–105. https://doi.org/10.1016/S0304-3835(02)00348-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-3835(02)00348-8</ArticleId>
            <ArticleId IdType="pubmed">12183081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, Wang YZ (2007) Blockage of intermediate-conductance-Ca<sup>2+</sup>-activated K<sup>+</sup> channels inhibits progression of human endometrial cancer. Oncogene 26:5107–5114. https://doi.org/10.1038/sj.onc.1210308</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1210308</ArticleId>
            <ArticleId IdType="pubmed">17310992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cherubini A, Taddei GL, Crociani O, Paglierani M, Buccoliero AM, Fontana L, Noci I, Borri P, Borrani E, Giachi M, Becchetti A, Rosati B, Wanke E, Olivotto M, Arcangeli A (2000) HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer 83(12):1722–1729. https://doi.org/10.1054/bjoc.2000.1497</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1054/bjoc.2000.1497</ArticleId>
            <ArticleId IdType="pubmed">11104572</ArticleId>
            <ArticleId IdType="pmc">2363441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Chen Q, Huang G, Guo X, Li N, Li Y, Li B (2018) BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway. BMC Cancer 18(1):1128. https://doi.org/10.1186/s12885-018-5027-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-5027-9</ArticleId>
            <ArticleId IdType="pubmed">30445932</ArticleId>
            <ArticleId IdType="pmc">6240221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Liu L, Li G, Xia M, Du C, Zheng Z (2018) The role of BKCa in endometrial cancer HEC-1-B cell proliferation and migration. Gene 655:42–47. https://doi.org/10.1016/j.gene.2018.02.055</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2018.02.055</ArticleId>
            <ArticleId IdType="pubmed">29477869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin LS, Park CC, Zitnay KM, Sinha M, DiPatri AJ, Perillá P, Simard M (1997) 4-Aminopyridine causes apoptosis and blocks an outward rectifier K<sup>+</sup> channel in malignant astrocytoma cell lines. J Neurosci Res 48(2):122–127. https://doi.org/10.1002/(SICI)1097-4547(19970415)48:2%3c122::AID-JNR4%3e3.0.CO;2-E</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-4547(19970415)48:2&lt;122::AID-JNR4&gt;3.0.CO;2-E</ArticleId>
            <ArticleId IdType="pubmed">9130140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS (1995) Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol 162(2):163–171. https://doi.org/10.1002/jcp.1041620202</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.1041620202</ArticleId>
            <ArticleId IdType="pubmed">7822427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hendriks R, Morest DK, Kaczmarek LK (2000) Role in neuronal cell migration for high-threshold potassium currents in the chicken hindbrain. J Neurosci Res 58(6):805–814. https://doi.org/10.1002/(SICI)1097-4547(19991215)58:6%3c805::AID-JNR7%3e3.0.CO;2-V</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-4547(19991215)58:6&lt;805::AID-JNR7&gt;3.0.CO;2-V</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jombai T (2011) In vitro ınhibitory activity of black seed oil and potassium chloride against biomarkers of triple negative breast cancer. MSc University of Louisiana State, Baton Rouge, LA</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
